The pharmaceutical landscape is constantly changing, with countries taking different approaches to ensure the safety and effectiveness of medications. China and Singapore are two vibrant markets experiencing an increasing demand for innovative drugs. However, the regulatory environments in both countries can be quite complex, posing challenges for those unfamiliar with the processes. This guide highlights the key differences and similarities in their pharmaceutical regulations. From regulatory frameworks and approval processes to market access and post-market surveillance, discover how both nations safeguard consumer drug safety and efficacy.

As more and more Chinese companies are looking to expand their pharmaceutical business abroad, Singapore could serve as a good base to start off with in the ASEAN region with clearly established guidelines and as a maturity level 4 agency recognized by WHO, having your dossier evaluated by HSA could indirectly mean that your product is supported by robust quality, clinical and safety data to support the intended usage accordance to approved indications.

You might wish to check out: https://theregconsultants.com/market-entry-guide-for-china-pharmaceutical-companies-to-enter-singapore/ for more information on some key barriers that you should work on.

Regulatory Frameworks

China’s primary regulatory body is the National Medical Products Administration (NMPA), responsible for managing pharmaceutical regulations. It formulates and organises the registration of pharmaceutical products, reviews applications, and decides whether to approve or reject them. The Drug Evaluation Centre (CDE) under the NMPA handles the review of clinical trials, marketing authorisation applications, and any supplementary or re-registration requests. Additionally, the Chinese Food and Drug Administration (CFDA/CNDA) oversees the safety and management of food, medical devices, health products, cosmetics, and drugs, operating directly under the State Council.

In contrast, Singapore’s Health Sciences Authority (HSA) serves as the key regulatory agency for medical and biological drugs. HSA adopts a streamlined approach, prioritising efficient regulation while upholding safety standards.

Understanding these regulatory frameworks is crucial for any company looking to navigate the complexities of country-specific drug regulations.

Approval Processes

When it comes to the pharmaceutical approval process, there are notable differences between the two nations. In China, new drug approvals often take longer due to rigorous clinical data requirements and comprehensive review procedures. However, recent reforms have been initiated to expedite drug approvals and bring it more in line with international standards. Conversely, Singapore offers a more streamlined approval pathway, enabling companies to get new pharmaceuticals to obtain marketing authorisation faster. This efficiency is especially attractive for businesses looking to gain pharma market access in a competitive environment.

Clinical Trial Requirements

Clinical trial requirements differ quite a bit between China and Singapore. In China, the regulatory landscape demands strict adherence to local standards, often leading to lengthy approval processes. NMPA requires extensive clinical data, which can be a challenge for international companies. In contrast, HSA has created a framework that supports clinical research, offering more flexibility and efficiency in trial designs. Singapore accepts foreign clinical data, which minimises the requirements to conduct local trials, unlike other neighbouring countries.

For new drug applications, most Chinese companies would have to register their product with US FDA making it an advantageous approach to enter Singapore via an expedited pathway with shorter time to market. The key point is that the application should be submitted within 3 years from date of approval and the dossier set as well as the proposed indications should be similar to what is proposed for Singapore registration.

Understanding these differences is crucial for companies looking to effectively plan their clinical strategies in both markets.

Market Access and Pricing

Drug market access strategies vary significantly between China and Singapore. China, with its large population and growing healthcare demands, presents a complex market that can be difficult to navigate. NMPA has established detailed pricing mechanisms and reimbursement frameworks, which require companies to conduct thorough market analysis. In Singapore, The Ministry of Health (MOH) maintains a list of subsidised drugs under the List of Subsidised Drug and Medication Assistance Fund (MAF). Drugs are categorised into different tiers based on their clinical efficacy and cost-effectiveness for treating common conditions. Although smaller, it is often more predictable, making it an appealing choice for pharmaceutical companies looking to expand into new markets.

Post-Market Surveillance

Post-market surveillance of pharmaceuticals is essential for maintaining drug safety once products are on the market. In China, NMPA uses stringent pharmacovigilance systems to track adverse effects and manage safety risks, requiring mandatory reporting from both healthcare professionals and companies. Similarly, Singapore’s HSA places a strong emphasis on drug safety through its comprehensive post-market surveillance protocols. This includes timely data collection and analysis to spot any potential issues with the pharmaceuticals in circulation.

You may also refer to the quick table below highlighting the regulatory similarities and differences between both countries for your quick access:

Navigating pharmaceutical regulations in China and Singapore requires a keen understanding of the factors discussed. For businesses looking to thrive in these markets, leveraging expert pharma regulatory services can be a game-changer. If you need guidance on registering pharmaceutical products or accessing these promising markets, The Reg Consultants can provide the support you need. With our experienced team of experts, we can assist you through every step of the registration process, ensuring a smoother journey toward compliance and success.

Contact us to learn more about our services and how we can help you get started today.

Accessing life-saving treatments can be challenging, particularly for those living with rare diseases. In Singapore, as in many other regions, orphan drugs — medications specifically created to treat these rare conditions — come with unique challenges regarding availability and cost. In this guide, we delve into the complex issues surrounding orphan drugs and offer a closer look at Singapore’s current pharma market access landscape.

Definition and Scope

According to the Medicines (Orphan Drugs) (Exemption) Order, rare diseases are life-threatening or severely debilitating conditions that affect fewer than 20,000 people. Orphan drugs in Singapore are defined as medicinal products that a doctor or dentist has identified as essential for treating a rare disease when no effective substitute is available. These drugs typically haven’t been licensed under the Medicine Act but have received approval from health authorities in their country of origin or other countries where they have been used.

While the prevalence of rare diseases in Singapore is relatively low compared to more common health issues, the impact on patients and their families can be significant. The rarity of these conditions makes rare diseases access and the development of effective treatments particularly challenging.

Research and Drug Development Challenges

Developing orphan drugs involves several significant hurdles. Pharmaceutical companies often face high costs and technical difficulties due to the small patient populations involved. Research and development (R&D) for these drugs requires substantial investment, yet there is no guarantee of a large market. The financial risks, coupled with complex clinical trial requirements, can discourage investment in orphan drug development. Consequently, many promising treatments never make it to market, leaving patients with few options.

Regulatory Framework

Singapore currently lacks orphan drug-specific registration guidance. However, under the Medicines (Orphan Drugs) (Exemption) Order, importers can bring in and supply these drugs without a product licence, provided that a doctor or dentist prescribes them for a patient under their care. These drugs must be stored in a hospital and managed by a custodian, who must be a physician, dentist, or pharmacist appointed by the hospital. Doctors or dentists needing these drugs for treatment must request them from the custodian. Additionally, while drug developers often benefit from expedited approval processes and incentives for the development and registration of pharmaceutical products, there are currently no regulatory incentives for these drugs in Singapore.

Cost and Affordability

One of the significant barriers to accessing orphan drugs is their high cost. Because these drugs are developed for small patient populations, the development expenses are spread across fewer individuals, leading to higher prices. In Singapore, like in many other countries, this places a financial burden on both patients and the healthcare system. To help address this, the Ministry of Health and SingHealth Fund established the Rare Disease Fund (RDF), a charitable fund that combines community donations with government matching contributions to support Singaporeans with rare diseases who need expensive treatments. However, the funding currently covers eight medications for five conditions.

Patient Advocacy and Support

Patient advocacy groups play a vital role in improving access to the drugs. These organisations work tirelessly to raise awareness, support affected families, and push for policy changes. In Singapore, patient groups are instrumental in bringing attention to the needs of those with rare diseases and advocating for regulatory and financial reforms. Their efforts help create a more supportive environment for accessing treatments and drive meaningful changes in policy and practice.

The challenges of accessing orphan drugs and treating rare diseases in Singapore are part of a broader global issue involving access and affordability. Overcoming the abovementioned hurdles requires collaboration among policymakers, healthcare providers, and patient advocates. For those seeking expert guidance on pharma regulatory services and market access, The Reg Consultants in Singapore provides valuable insights and support to help navigate these intricate processes. 

Get in touch with us today to discover how we can assist with your needs.

Navigating the complexities of therapeutic product licences in Singapore is important for pharmaceutical and medical device businesses to maintain regulatory compliance. When there are changes to a product’s safety, efficacy, quality, or forensic classification changes after registration of the pharmaceutical products, understanding the process and requirements for licence variations becomes crucial. This guide offers an overview of variation types, the submission process, necessary documentation, regulatory requirements, and the importance of post-approval monitoring.

Types of Variations

Post-approval variations to therapeutic product licences in Singapore are classified as either major or minor. Major variations involve significant changes to the approved indication, route of administration, dosing regimen, intended use, or forensic classification, and require a thorough review by the Health Sciences Authority (HSA), potentially including additional clinical data. On the other hand, minor variations entail less significant changes, such as updates to labelling or packaging , change in address of the manufacturer, submission of CEP in replacement of DMF, etc.  While less complex, they still require careful assessment against what was previously approved and submitted  to ensure compliance with regulatory standards.

Variation Submission Process

Submitting a variation application to the HSA follows a systematic process. Begin by determining the type based on the proposed changes. Follow the appropriate checklist and prepare the documentation appropriate to the category of the MIV.  The last step is to apply through HSA’s online portal, PRISM. Make sure that all the necessary information is complete and accurate to avoid delays. HSA will review the submission and may request additional information if needed. Upon review completion, input requests will be issued if there are any questions, if not you will receive an email notification to inform you of the status of the variation. Do note that for minor variation, only one minor variation can be submitted at all times. Certain minor variations don’t require prior approval, but the application must be submitted within six months of the changes. Additionally, the HSA provides a self-guided tool to assist with minor variation applications. ​​For further details, please visit HSA’s website.

Licence Variation Documentation

The documentation required for licence variations depends on the proposed change type. Major variations typically require detailed information, including new clinical data, revised product specifications, and updated risk assessments. Conversely, minor variations generally need less extensive documentation, such as updated labels or packaging inserts. Providing comprehensive and accurate documentation is vital to meet regulatory expectations and facilitate a smooth approval process.

Singapore Regulatory Guidelines

The regulatory guidelines for variation of therapeutic product licences in Singapore are designed to maintain the safety and efficacy of medical products. HSA mandates adherence to specific guidelines regarding the changes that require approval and the documentation for each type. Familiarity with these guidelines helps streamline the submission process and supports successful pharma market access by ensuring that all regulatory requirements are fulfilled, thereby reducing the risk of non-compliance.

Post-Approval Monitoring

Finally, post-approval monitoring is crucial to upholding the safety and efficacy of therapeutic products. Ongoing surveillance and reporting are necessary to track the product’s performance in the market after a variation is approved. This includes monitoring for any adverse effects or issues that may arise and promptly reporting them to the HSA. Effective post-approval monitoring helps verify that the product continues to meet regulatory standards and remains safe for use.

Managing changes to therapeutic product licences in Singapore is key to staying compliant with regulations. Understanding these factors will help you avoid common pitfalls and ensure that your products remain compliant throughout their lifecycle. 

For expert guidance and comprehensive support with therapeutic product licences in Singapore, our team at The Reg Consultants is always ready to help. We are well-versed in licence variations, submission processes, and regulatory compliance. Discover how our pharma regulatory services can ensure your products meet all necessary standards and maintain their market readiness. 

For companies that already have a mature product pipeline which requires maintenance activities, do check our advance subscription plan for more information. 

Visit our website today and let us help you achieve seamless regulatory compliance.

Have you ever wondered what the difference between the terms “biosimilar” and “generic drugs” is? In the pharmaceutical industry, the distinctions between biosimilar and generic drugs play an important role in affecting healthcare accessibility and affordability, particularly in the context of pharmaceutical product registration. This guide explores the contrasting regulatory frameworks for biosimilars and generics, their development and approval processes, and their impact on the healthcare industry.

Biosimilar drugs are highly similar to biologic drugs, which are derived from living organisms. While they are not identical to the original biologics, they are designed to match the reference product in terms of quality, safety, and efficacy. Due to the complexity of biologics, biosimilars require rigorous testing and regulatory approval. The difference between biosimilar and generic drugs lies in the nature of the original products—biologics versus chemically synthesised drugs.

Generic drugs are chemically equivalent to brand-name drugs and contain the same active ingredients, dosage, and efficacy. They are generally more affordable as they do not require the same extensive testing as the original branded drug, focusing instead on proving bioequivalence. The difference between biosimilar and generic drugs lies in the fact that generic drugs are simpler, chemically synthesised versions of brand-name pharmaceuticals, whereas biosimilars are derived from biological sources.

Definition and Development

At first glance, biosimilars and generics seem similar as both provide affordable alternatives to established medications. However, a major difference between biosimilar and generic drugs lies in their origin and the regulations governing their development.

Generic drugs are exact copies of small-molecule brand-name drugs, where the manufacturing process can be precisely replicated. These drugs contain identical active ingredients, dosages, and formulations, allowing them to be approved through a more straightforward regulatory process, focused on proving bioequivalence. This means that the generic drug delivers the same amount of active ingredient into the bloodstream as the original, ensuring similar therapeutic effects.

Biosimilar drugs, on the other hand, are biologics derived from living sources, such as plant or animal cells, making their structures more complex and less defined. Because of their biological nature, creating an exact copy of a biologic is impossible. As a result, biosimilars require a more rigorous approval process that involves comparative studies to demonstrate that they have no clinically meaningful differences in safety, efficacy, and biological activity from the reference product. The difference between biosimilar and generic drugs is primarily based on their complexity and the necessity for comprehensive comparability studies in biosimilars.

Approval Process

The governing regulatory authority in Singapore for health products is the Health Sciences Authority (HSA), which plays a vital role in verifying the safety and efficacy of both biosimilars and generics. Nevertheless, the registration process for each category differs due to the difference between biosimilar and generic drugs.

Generic drugs typically follow a well-established pathway that focuses on demonstrating bioequivalence, meaning the drug delivers the same active ingredient to the body as the original. In contrast, biosimilars undergo a more rigorous assessment to establish a high level of similarity to the reference product (the original biologic) in terms of quality, safety, efficacy, and biological activity. This often involves extensive analytical studies and clinical trials, reflecting the more complex nature of biologics.

Efficacy and Safety

In regulatory assessments, both biosimilars and generics must demonstrate efficacy and safety. However, the difference between biosimilar and generic drugs lies in their approval process. While generics must prove bioequivalence to a brand-name drug, biosimilars must establish their similarity to the biologic reference product by matching its safety and efficacy profile through comprehensive testing.

Market Access and Affordability

The introduction of both biosimilars and generics has had a significant impact on the pharmaceutical market. The difference between biosimilar and generic drugs is primarily their origin—biosimilars are derived from biologics, while generics are chemically synthesised versions of brand-name drugs. Both types of drugs offer substantial cost savings, and have greatly improved access to affordable healthcare.

Physician and Patient Considerations

While both biosimilar and generic drugs offer significant benefits, healthcare providers must carefully consider their interchangeability. The difference between biosimilar and generic drugs becomes crucial when deciding on treatments, as biosimilars may not always be substituted for the original biologic, unlike generics, which can often replace brand-name drugs without complications. The decision should be made in consultation with a qualified healthcare professional who can evaluate the patient’s specific needs and medical history.

Understanding the difference between biosimilar and generic drugs helps healthcare providers and regulatory stakeholders navigate the approval processes. Recognising the distinct pathways for both categories ensures safe and effective medication options for patients.

For expert guidance on navigating the complexities of pharmaceutical registration in Singapore, consider partnering with a reputable consultancy firm like The Reg Consultants. Our team of regulatory specialists offers comprehensive pharma regulatory services and possesses in-depth knowledge of the local landscape for biosimilars and generics. We can guide you through the intricate approval process, ensuring your products meet all regulatory requirements.

Understanding the difference between biosimilar and generic drugs is crucial to positioning your product accurately in the market. Contact The Reg Consultants today to leverage our expertise and ensure a seamless regulatory journey tailored to your specific needs.

Frequently Asked Questions

1. What is the difference between biosimilars and generic drugs?

The primary difference is that biosimilars are derived from biologic drugs, while generics are chemically identical to brand-name drugs. Biosimilars require more rigorous testing to prove similarity to biologics.

2. What is crucial for a biosimilar application in Singapore?

It is important to find out what is the Singapore Biological Reference Product so as to build comparative quality, PK and PD profile for registration.

3. What is the registration process for biosimilars in Singapore?

In Singapore, the registration process for biosimilars involves submitting a comprehensive application to the Health Sciences Authority (HSA) via the NDA-2 route and obtaining prior approval from reference agencies such as EMA, FDA, TGA. The application process typically takes about 230 working days.

4. Are clinical trials required for biosimilar registration in Singapore?

Yes, clinical trials may be required as part of the registration process for biosimilars in Singapore. The extent of required trials depends on the degree of similarity established through analytical studies and the specific characteristics of the biosimilar.

5. What documentation is needed for biosimilar registration?

The documentation needed for biosimilar registration typically includes a detailed dossier containing information on the manufacturing process, quality control measures, preclinical and clinical study results, and any other relevant information to support the application.

Please link to my articles that I have written previously:

Generic: https://theregconsultants.com/overcoming-the-challenges-of-registration-of-a-generic-drug-in-singapore/ 

Biosimilar; https://theregconsultants.com/quick-overview-of-biosimilar-registration-in-singapore/ 

Get in touch with us today to find out how we can tailor our services to fit your needs.

In today’s fast-paced society, maintaining a healthy diet has never been more relevant. Nutraceuticals, or health supplements, are becoming increasingly popular for their role in maintaining overall health and supplementing nutrients lacking in our daily diets. These products are typically derived from natural and organic sources, catering to growing interests in areas such as immunity, joint support, sports nutrition, and heart health. Additionally, immunity boosters, cholesterol-lowering agents, fish oil, skin and hair-strengthening supplements, collagen supplements and fat-burning supplements are some of the highest-selling products in the market. 

Yet, the absence of unified regulations in certain aspects, such as labelling, might complicate product marketing across ASEAN countries and limit consumer access. In this article, we will delve into the complexities of complying with multiple local protocols while highlighting the importance of product safety and market entry.

• Harmonised Standards

In 2004, the ASEAN Economic Community established the Traditional Medicines and Health Supplements Product Working Group (TMHS PWG) to unify technical requirements for nutraceutical or health supplements and traditional medicines across the region. The group developed ten core annexes or technical requirements essential to harmonisation efforts. However, these have yet to be fully implemented as they require the ratification document to be signed by ASEAN trade ministers.

ASEAN Harmonised Technical Guidelines and Standards for Health Supplements

• Annex I– ASEAN Guiding Principles for Inclusion Into or Exclusion From the Negative List of Substances for Health Supplements
• Annex II– ASEAN Guiding Principles for the Use of Additives and Excipients in Health Supplements
• Annex III – ASEAN Guidelines on Limits of Contaminants for Health Supplements
• Annex IV – ASEAN Guidelines for Minimising the Risk of Transmission of Transmissible Spongiform Encephalopathies in Health Supplements
• Annex V – ASEAN Guidelines on Stability and Shelf-Life of Health Supplements
• Annex VI – ASEAN Guiding Principles on Safety Substantiation of Health Supplements
• Annex VII – ASEAN Guidelines on Claims and Claims Substantiation for Health Supplements
• Annex VIII – ASEAN Guideline on Good Manufacturing Practice for Health Supplements
• Annex IX – ASEAN Guidelines on Labelling Requirements for Health Supplements
• Annex X – ASEAN General Principles for Establishing Maximum Levels of Vitamins and Minerals in Health Supplements

Despite this, countries like Singapore, Malaysia, Brunei, Thailand, and Myanmar have begun adopting these standards, especially for the inclusion or exclusion of substances on the negative list. Though yet to be ratified, they provide a uniform framework, simplifying approvals and facilitating market entry. Adherence ensures products meet safety and quality criteria, which is crucial for consumer confidence and market success.

• Registration Process

Registering a nutraceutical product in the ASEAN region usually involves several steps, which can vary slightly from country to country. Typically, this includes submitting detailed product information, safety data, and efficacy studies to the relevant regulatory authority. Despite these variations, all countries stress the importance of thorough documentation and adherence to local regulations. Understanding these steps enables companies to plan effectively and prevent delays in the registration of pharmaceutical products and dietary supplements.

• Labelling Requirements

Among the many regulations to follow, labelling stands out as one of the most crucial aspects. Mandatory information often includes the product name, the name and strength of the active ingredients, usage instructions, and any necessary warnings. Labels must be clear, accurate, and in the appropriate languages used in the countries where the product will be sold. Adhering to these guidelines when introducing nutraceuticals into the ASEAN region makes sure that consumers receive the necessary information for safe and effective product use.

For detailed labelling requirements, refer to the ASEAN guidelines on labelling requirements.

• Permissible Ingredients

Furthermore, each ASEAN country maintains a list of approved ingredients for nutraceutical products, aligned with ASEAN guidelines that determine which substances are permitted or restricted. These lists often impose restrictions on certain substances for safety and efficacy reasons. Companies must stay informed about these lists and verify that their products comply with regulatory standards by avoiding prohibited ingredients. This vigilance not only helps minimise regulatory risks but also certifies that the products are safe for consumers.

Read more: ASEAN Guiding Principles for Inclusion Into or Exclusion from the Negative List of Substances for Health Supplements.

• Market Access Challenges

Gaining market access in the ASEAN region involves navigating diverse regulatory requirements and addressing local market conditions, which can pose significant challenges. Companies often encounter hurdles such as varying approval timelines, different documentation requirements, and cultural nuances affecting product acceptance. Overcoming these challenges requires strategic approaches such as conducting thorough market research, collaborating with local regulatory specialists, and remaining flexible to adapt to evolving procedures and market dynamics.

Navigating nutraceutical regulations in the ASEAN region requires a thorough understanding of the factors listed above. With the right insights and the support of regulatory affairs services, you can ensure compliance and successfully enter the ASEAN market. If you need guidance, consider reaching out to The Reg Consultants in Singapore. Our team offers comprehensive services to help you achieve regulatory compliance.

Contact us today to explore how we can support your market entry into the ASEAN region.